Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Virax Biolabs Group Ltd. Class A ( (VRAX) ).
On June 13, 2025, Virax Biolabs Group Limited announced the resignation of Jason Davis from his roles as Chief Financial Officer and Secretary. His departure is not due to any disagreements with the company’s operations or policies. Despite his resignation, Mr. Davis will continue to support the company as an independent consultant, focusing on audit coordination and financial administration.
The most recent analyst rating on (VRAX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Virax Biolabs Group Ltd. Class A stock, see the VRAX Stock Forecast page.
More about Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Limited is a company based in the United Kingdom, operating within the biolabs industry. The company focuses on providing innovative solutions and services in the biotechnology sector.
Average Trading Volume: 143,189
Technical Sentiment Signal: Sell
Learn more about VRAX stock on TipRanks’ Stock Analysis page.